Aligos Therapeutics
PublicAligos Therapeutics is now publicly traded
The data on this page reflects Aligos Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 15, 2020
Last Round
Private Placement
Feb 12, 2025
Total Funding Raised
$673.55M
Company Overview
Aligos Therapeutics (NAS: ALGS) is a biopharmaceutical company focused on developing innovative therapies for viral and liver diseases, including chronic hepatitis B, coronaviruses, and nonalcoholic steatohepatitis (NASH).
Sector
Biotech
AI Layer
Non-AI
Keywords
Aligos Therapeutics Comparables
Compare Aligos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NorthSea Therapeutics | 74% | |
| AusperBio | 72% | |
| Cyta Therapeutics | 68% |
Aligos Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Feb 12, 2025 | ||||
| Private Placement | Oct 23, 2023 | ||||
| Follow-on Offering | Jun 30, 2021 | ||||
| IPO | Oct 15, 2020 | ||||
| Series B | Jan 10, 2020 | ||||
Series A | Aug 1, 2018 |
Aligos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Private Placement |
| Jefferies | Follow-on Offering, IPO |
| Janus Henderson Group | Series B |
| Boxer Capital | Series B |
| Deep Track Capital | Private Placement |
| Logos Capital | Series B |
| Pivotal bioVenture Partners | Series B |
Aligos Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access